Abstracts tagged "tumor necrosis factor (TNF) and uveitis"

Abstract Number: 1516 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors
M. Victoria Hernández¹, Marina Mesquida¹, Victor Llorens², Maite Sainz de la Maza², Ricardo Blanco³, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Ana Urruticoechea-Arana⁷, Juan Ramon De Dios⁸, Pilar Ahijado-Guzman⁹, Enrique Judez¹⁰, Patricia Tejón¹¹, M Soledad Peña¹², Francisca Sivera¹³, Alfredo Adan¹ and Raimon Sanmarti¹⁴, ¹Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla., Santander, Spain, ⁵Hospital Donostia. Spain, San Sebastian, Spain, ⁶Ophthalmology Department. Hospital Donostia, San Sebastian, Spain, ⁷Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁸Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, ⁹Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ¹⁰Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹¹Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophtalmology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹³Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, ¹⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Uveitis is a common extra-articular manifestation in patients with spondyloarthritis (SpA) requiring, in most severe cases, the use of biological therapy, especially tumour necrosis…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 1455 • 2016 ACR/ARHP Annual Meeting
Collagen-Induced Arthritis and Uveitis in Mice Lacking TNF Receptors
Chiharu Iwahashi¹, Minoru Fujimoto², Tomoharu Ohkawara³, Hayato Urushima¹, Satoshi Serada¹ and Tetsuji Naka⁴, ¹Laboratory for Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ²Laboratry of immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ³Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan, ⁴Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan
Background/Purpose: Tumor necrosis factor (TNF) is a critical effector of the autoimmune inflammation in rheumatoid arthritis (RA) and uveitis. TNF inhibitors are preferably used in…
Abstract Number: 2038 • 2015 ACR/ARHP Annual Meeting
Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids
Antoine P. Brezin¹, Phillippe Kestelyn², Joachim Van Calster³, Glenn J. Jaffe⁴, Jennifer E. Thorne⁵, David Scales⁶, Pablo Franco⁷, Andrew D. Dick^8,9,10, Quan Dong Nguyen¹¹, Eric B. Suhler^12,13, Anne Camez¹⁴, Alexandra P. Song¹⁵, Martina Kron¹⁴, Samir Tari¹⁵, James T. Rosenbaum^16,17 and Arnd Heiligenhaus¹⁸, ¹Université Paris Descartes, Hôpital Cochin, Paris, France, ²Ghent University Hospital, Ghent, Belgium, ³University Hospitals Leuven, Leuven, Belgium, ⁴Duke University, Durham, NC, ⁵Johns Hopkins Medical Institute, Baltimore, MD, ⁶University of Texas Health Science Center, San Antonio, TX, ⁷Organización Médica de Investigación (OMI), Buenos Aires, Argentina, ⁸National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital, London, United Kingdom, ⁹University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ¹⁰University College London, Institute of Ophthalmology, London, United Kingdom, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, ¹²VA Portland Health Care System, Portland, OR, ¹³Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ¹⁴Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹⁵AbbVie Inc., North Chicago, IL, ¹⁶Devers Eye Institute, Legacy Hospital system, Portland, OR, ¹⁷Casey Eye Institute, Oregon Health & Science University, Portland, OR, ¹⁸Department of Ophthalmology at St. Franziskus Hospital Muenster, University of Duisberg-Essen, Muenster, Germany
Background/Purpose: Corticosteroids, currently the mainstay of uveitis treatment, are associated with adverse events and are not always fully effective. Multiple reports describe the use of…